deltatrials
Completed PHASE2 NCT00001357

Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions HIV Infection
Interventions Interleukin-2
Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Aug 31, 1993 Completion: Apr 30, 2002

A PHASE2 clinical study on HIV Infection, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 5 data snapshots since 1993. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Aug 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States